COVID-19 mRNA vaccines

J Genet Genomics. 2021 Feb 20;48(2):107-114. doi: 10.1016/j.jgg.2021.02.006. Epub 2021 Mar 15.

Abstract

The ongoing COVID-19 pandemic and its unprecedented global societal and economic disruptive impact highlight the urgent need for safe and effective vaccines. Taking substantial advantages of versatility and rapid development, two mRNA vaccines against COVID-19 have completed late-stage clinical assessment at an unprecedented speed and reported positive results. In this review, we outline keynotes in mRNA vaccine development, discuss recently published data on COVID-19 mRNA vaccine candidates, focusing on those in clinical trials and analyze future potential challenges.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Binding Sites / genetics
  • Binding Sites / immunology
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • COVID-19 / virology
  • COVID-19 Vaccines / genetics
  • COVID-19 Vaccines / immunology*
  • COVID-19 Vaccines / therapeutic use
  • Drug Development
  • Humans
  • Pandemics / prevention & control
  • RNA, Messenger / genetics
  • RNA, Messenger / immunology*
  • RNA, Messenger / metabolism
  • SARS-CoV-2 / immunology*
  • SARS-CoV-2 / metabolism
  • SARS-CoV-2 / physiology
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology*
  • Viral Proteins / genetics
  • Viral Proteins / immunology
  • Viral Proteins / metabolism
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic
  • Viral Proteins